Next 10 |
The biotechnology sector largely underperformed the broader market this year, particularly small- to mid-cap biotech indexes whose constituents tend to experience more volatility. Contributing factors to the market decline include fears of increased regulation and oversight of M&A...
M&A activity increases with eight new deals announced. Welbilt terminates its deal with The Middleby Corporation and agrees to be acquired by Ali Group. Monmouth Real Estate Investment Corporation receives an unsolicited acquisition proposal from a large private investment fir...
Zhanna Hapanovich/iStock via Getty Images MorphoSys AG (MOR) announced the completion of the previously-announced cash tender offer for all outstanding shares of Constellation Pharmaceuticals (CNST) which is in a deal to be acquired by the company for $1.7B. The transaction was financed by an...
Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its...
janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to Jefferies. Biotech deals may pick up after a 3-6 month of a large "drawdown" and as prices "normalize" f...
Over 70 multi-billion dollar deals announced in the first half of the year. SPAC IPOs pick up pace and Chamath Palihapitiya files four new biotech focused SPACs. Icon completes the acquisition of PRA Health Sciences. For further details see: Merger Arbitrage Mondays - MK...
MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Constellation P...
Zhanna Hapanovich/iStock via Getty Images Constellation Pharmaceuticals (CNST) said the waiting period under the HSR act expired for its planned $1.7B sale to MorphoSys (MOR) expired yesterday. Conditions on the offer have been satisfied, according to an 8-K filing. Last month, MorphoSys...
NEW YORK, NY / ACCESSWIRE / June 30, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: County Bancorp, Inc. (NASDAQ:ICBK) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties r...
NEW YORK, NY / ACCESSWIRE / June 21, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) concerning potential violations of the federal securities laws and/or breaches of fid...
News, Short Squeeze, Breakout and More Instantly...
Constellation Pharmaceuticals Inc. Company Name:
CNST Stock Symbol:
NASDAQ Market:
Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its...
MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Constellation P...
Translational data support the disease-modifying potential of pelabresib Central pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib treatment observed across a wide range of myelofibrosis patient subgroups...